JP6463333B2 - オキシカルバゼピンの急速分散性の剤形 - Google Patents

オキシカルバゼピンの急速分散性の剤形 Download PDF

Info

Publication number
JP6463333B2
JP6463333B2 JP2016502709A JP2016502709A JP6463333B2 JP 6463333 B2 JP6463333 B2 JP 6463333B2 JP 2016502709 A JP2016502709 A JP 2016502709A JP 2016502709 A JP2016502709 A JP 2016502709A JP 6463333 B2 JP6463333 B2 JP 6463333B2
Authority
JP
Japan
Prior art keywords
matrix
oxc
dosage form
drug
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016502709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513724A5 (enExample
JP2016513724A (ja
Inventor
ジュール・ジェイコブ
ケリー・カプート
マイケル・ギロー
ケネス・ジェイ・サルツボー
トーマス・ジー・ウェスト
Original Assignee
アプレシア・ファーマスーティカルズ・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプレシア・ファーマスーティカルズ・カンパニー filed Critical アプレシア・ファーマスーティカルズ・カンパニー
Publication of JP2016513724A publication Critical patent/JP2016513724A/ja
Publication of JP2016513724A5 publication Critical patent/JP2016513724A5/ja
Application granted granted Critical
Publication of JP6463333B2 publication Critical patent/JP6463333B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/10—Processes of additive manufacturing
    • B29C64/165—Processes of additive manufacturing using a combination of solid and fluid materials, e.g. a powder selectively bound by a liquid binder, catalyst, inhibitor or energy absorber
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y70/00—Materials specially adapted for additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0058—Liquid or visquous
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/25—Solid
    • B29K2105/251—Particles, powder or granules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016502709A 2013-03-15 2014-03-14 オキシカルバゼピンの急速分散性の剤形 Active JP6463333B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791726P 2013-03-15 2013-03-15
US61/791,726 2013-03-15
PCT/US2014/028125 WO2014143935A1 (en) 2013-03-15 2014-03-14 Rapidly dispersible dosage form of oxcarbazepine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018172088A Division JP2019006812A (ja) 2013-03-15 2018-09-14 オキシカルバゼピンの急速分散性の剤形

Publications (3)

Publication Number Publication Date
JP2016513724A JP2016513724A (ja) 2016-05-16
JP2016513724A5 JP2016513724A5 (enExample) 2017-04-06
JP6463333B2 true JP6463333B2 (ja) 2019-01-30

Family

ID=51537567

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502709A Active JP6463333B2 (ja) 2013-03-15 2014-03-14 オキシカルバゼピンの急速分散性の剤形
JP2018172088A Abandoned JP2019006812A (ja) 2013-03-15 2018-09-14 オキシカルバゼピンの急速分散性の剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018172088A Abandoned JP2019006812A (ja) 2013-03-15 2018-09-14 オキシカルバゼピンの急速分散性の剤形

Country Status (10)

Country Link
US (4) US9314429B2 (enExample)
EP (1) EP2968354B1 (enExample)
JP (2) JP6463333B2 (enExample)
CN (1) CN105050604B (enExample)
AU (2) AU2014228063B2 (enExample)
CA (1) CA2906107C (enExample)
ES (1) ES2761265T3 (enExample)
HK (1) HK1213472A1 (enExample)
MX (1) MX364381B (enExample)
WO (1) WO2014143935A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CN109908355B (zh) 2013-03-15 2022-11-15 阿普雷奇亚制药有限责任公司 包含左乙拉西坦的快速分散剂型
US10716648B2 (en) * 2014-05-02 2020-07-21 University Of Louisville Research Foundation, Inc. Methods for fabricating dental restorations
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
CN105770899A (zh) * 2016-03-07 2016-07-20 北京诺康达医药科技有限公司 一种大剂量药物的速释制剂及其制备方法
AU2017235598A1 (en) * 2016-03-18 2018-08-09 Grünenthal GmbH Floating pharmaceutical dosage form
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
GB201612853D0 (en) 2016-07-25 2016-09-07 Univ Central Lancashire Solid dosage form production
JP7191385B2 (ja) 2017-01-26 2022-12-19 トリアステック インコーポレイテッド 特定の胃腸部位での制御放出の剤形
US10703549B2 (en) * 2017-06-30 2020-07-07 The Procter And Gamble Company Water soluble containers and methods of making them
ES3009585T3 (en) * 2017-10-26 2025-03-27 Merck Patent Gmbh Methods for performing cell culture
CN111698983B (zh) 2018-01-09 2022-10-18 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
JP7614103B2 (ja) * 2018-10-15 2025-01-15 アプレシア・ファーマスーティカルズ・エルエルシー 包装内に剤形を形成する方法およびシステム
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3913243A4 (en) 2019-01-18 2022-10-19 IHI Corporation PRINT FOIL STORE
EP3789015A1 (en) * 2019-09-05 2021-03-10 Universität Innsbruck Fast consolidating compounds
ES2828509B2 (es) 2019-11-26 2022-03-09 Fund Idonial Composicion para la impresion 3d de farmacos semisolidos
JP2023522035A (ja) * 2020-04-15 2023-05-26 アプレシア・ファーマスーティカルズ・エルエルシー 多成分パッケージ化投薬形態および方法
WO2021263132A1 (en) * 2020-06-26 2021-12-30 Aprecia Pharmaceuticals LLC Rapidly-orodispersible tablets having an interior cavity
KR20250050100A (ko) * 2022-08-18 2025-04-14 메르크 파텐트 게엠베하 고체 약학 투여 형태의 제조 방법
WO2024108082A1 (en) 2022-11-18 2024-05-23 Aprecia Pharmaceuticals LLC Orodispersive dosage forms containing droxidopa
FR3162625A1 (fr) * 2024-05-30 2025-12-05 Mb Therapeutics Formulation pharmaceutique imprimable par extrusion, cartouche d’impression renfermant une telle formulation et procédé de préparation d’un médicament la mettant en œuvre

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
WO1995001782A2 (en) 1993-07-09 1995-01-19 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5490962A (en) * 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US5738875A (en) 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
WO1998036738A1 (en) * 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
EE05147B1 (et) 1999-07-09 2009-04-15 Ortho-Mcneil Pharmaceutical, Inc. Suukaudselt manustatav maskeeritud maitsega vedel preparaat
DE19940944B4 (de) 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
DE60116758T2 (de) * 2000-05-18 2006-11-02 Therics, Inc. Einkapselung eines toxischen kerns in einen nicht-toxischen bereich in einer oralen darreichungsform
DE60226012T2 (de) 2001-03-05 2009-05-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Geschmacksmaskierte pharmazeutische formulierungen
EA200301223A1 (ru) * 2001-05-18 2004-08-26 Рэнбакси Лабораториз Лимитед Лекарственные формы окскарбазепина
EP1439824A2 (en) * 2001-10-29 2004-07-28 Therics, Inc. Three-dimensional suspension printing of dosage forms
EP1536774A1 (en) 2002-09-04 2005-06-08 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
EP1581197A1 (en) 2002-12-11 2005-10-05 Ranbaxy Laboratories, Limited Coating composition for taste masking coating and methods for their application and use
NZ544007A (en) 2003-05-07 2009-05-31 Samyang Corp Highly plastic granules for making fast melting tablets
FR2858556B1 (fr) 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
WO2005020961A1 (en) 2003-08-28 2005-03-10 Sandoz Ag Pharmaceutical composition comprising anticonvulsant with taste mask coating
US20060127479A1 (en) 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US20060182796A1 (en) 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
AU2007211210A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
US20070248684A1 (en) * 2006-01-31 2007-10-25 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
WO2007089247A1 (en) 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
EP2010499A4 (en) * 2006-04-21 2012-07-18 Alphapharm Pty Ltd PHARMACEUTICAL COMPOSITION OF OXCARBAZEPINE PARTICULATE FROM 15 TO 30 MICRONS IN AVERAGE
WO2008141751A2 (en) * 2007-05-23 2008-11-27 Ratiopharm Gmbh Pharmaceutical compositions comprising oxcarbazepine
US20120040001A1 (en) 2009-02-12 2012-02-16 Fuji Chemical Industry Co., Ltd. Disintegrating particle composition and rapidly disintegrating compression-molded material used the same
US20100285130A1 (en) 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
JP2012528819A (ja) 2009-06-04 2012-11-15 ビーエーエスエフ ソシエタス・ヨーロピア 味マスク活性成分含有口腔内崩壊性投薬形態
US20120207836A1 (en) 2009-08-19 2012-08-16 Bayer Pharma Aktiengesellschaft Drug delivery systems (wafer) for pediatric use
UY33173A (enExample) 2010-01-08 2011-07-29 Eurand Inc
US9381154B2 (en) * 2011-06-09 2016-07-05 Xerox Corporation Direct inkjet fabrication of drug delivery devices

Also Published As

Publication number Publication date
US20160250145A1 (en) 2016-09-01
EP2968354A1 (en) 2016-01-20
WO2014143935A1 (en) 2014-09-18
HK1214173A1 (en) 2016-07-22
CA2906107A1 (en) 2014-09-18
CA2906107C (en) 2021-08-24
EP2968354A4 (en) 2016-01-20
HK1213472A1 (zh) 2016-07-08
US9314429B2 (en) 2016-04-19
EP2968354B1 (en) 2019-11-13
WO2014143935A4 (en) 2014-11-20
MX2015012136A (es) 2015-11-25
AU2014228063A1 (en) 2015-10-08
US20170172919A1 (en) 2017-06-22
US10028909B2 (en) 2018-07-24
AU2017203365B2 (en) 2019-07-25
MX364381B (es) 2019-04-25
US20150366802A1 (en) 2015-12-24
ES2761265T3 (es) 2020-05-19
US20180296479A1 (en) 2018-10-18
JP2016513724A (ja) 2016-05-16
AU2017203365A1 (en) 2017-06-08
CN105050604B (zh) 2021-10-26
AU2014228063B2 (en) 2017-04-20
US9616018B2 (en) 2017-04-11
JP2019006812A (ja) 2019-01-17
CN105050604A (zh) 2015-11-11

Similar Documents

Publication Publication Date Title
JP6463333B2 (ja) オキシカルバゼピンの急速分散性の剤形
JP6466399B2 (ja) トピラマートの急速分散性の剤形
US12396979B2 (en) Rapid disperse dosage form
HK1214173B (en) Rapidly dispersible dosage form of oxcarbazepine
HK1214768B (en) Rapidly dispersible dosage form of topiramate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151112

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20151028

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20151112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180914

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20181108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181228

R150 Certificate of patent or registration of utility model

Ref document number: 6463333

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250